Newsroom
Eli Lilly Announces Acquisition of Merdia Biosciences for Up to $2.88 Billion
By KlickAnalytics Data Insights | August 31, 2026 08:02PM ET
Key Points
- Eli Lilly is set to acquire Merdia Biosciences for nearly $2.88 billion in cash
- The acquisition will add another early-stage biotechnology asset to Eli Lilly's immunology pipeline
- Trump is expected to announce new drug pricing deals with nearly a dozen drugmakers
- Eli Lilly continues its deal-making push to broaden its treatments for immune-related and allergic diseases
- The acquisition of Merdia Biosciences strengthens Lilly's immunology capabilities and its opportunity to elevate the standard of care for immune-mediated conditions with high unmet need
Eli Lilly, a pharmaceutical giant, has announced its plans to acquire Merdia Biosciences for up to $2.88 billion, in a move to expand its portfolio of treatments for immune-related and allergic diseases. The acquisition of Merdia Biosciences, a clinical-stage biotech company, will bring another early-stage biotechnology asset to Eli Lilly's immunology pipeline. The uniqueness of Merdia Biosciences was a clear attraction for the pharmaceutical giant, as it continues its push to diversify beyond its blockbuster obesity and diabetes franchises.
In addition to the acquisition, President Donald Trump is reportedly set to announce new drug pricing deals with nearly a dozen drugmakers. These deals are expected to see the drugmakers voluntarily sell their medications at lower prices, in line with the Trump administration's efforts to link the nation's drug prices to cheaper ones abroad.
The acquisition of Merdia Biosciences is part of Eli Lilly's ongoing deal-making push to broaden its treatments for immune-related and allergic diseases. The company has been actively seeking strategic acquisitions to strengthen its immunology capabilities and address high unmet needs in the market. This deal comes as part of Lilly's increased deal spending this year, as it looks to expand its portfolio and drive growth.
Eli Lilly's acquisition of Merdia Biosciences marks the latest move by the pharmaceutical giant to bolster its portfolio through strategic acquisitions. Merdia Biosciences, known for its autoimmune drugs, will further enhance Lilly's offerings in the immunology space. The acquisition will strengthen Lilly's position in developing treatments for serious autoimmune and allergic diseases, further elevating the standard of care in these areas.
Furthermore, Eli Lilly recently announced 52-week results from Phase 3b clinical trials evaluating the concomitant use of Taltz and Zepbound in adults with moderate-to-severe plaque psoriasis or active psoriatic arthritis, alongside obesity or overweight with additional weight-related comorbid conditions. The data showed improved and durable efficacy at one year, with Taltz and Zepbound maintaining or further improving disease activity from Week 36, demonstrating superior outcomes compared to Taltz alone in certain exploratory endpoints.
The acquisition of Merdia Biosciences by Eli Lilly for up to $2.88 billion in cash is a strategic move to expand the pharmaceutical giant's immunology pipeline. With a focus on developing treatments for immune-related and allergic diseases, Lilly continues to strengthen its position in the market through strategic acquisitions. The deal not only enhances Lilly's immunology capabilities but also underscores its commitment to addressing high unmet needs in the treatment of serious autoimmune conditions.
For more information:
Ask the market a question. Get a calculated answer.
The AI is not a chatbot bolted onto a document store. It calls the same analytics engine that powers every screen on this platform — so what comes back is a number it computed from raw history, with the command that produced it.
86,000+ instruments
Global equities, ETFs, funds, options, FX, commodities, crypto, economics, filings, transcripts and news — one normalised symbol universe with adjusted history.
A real analytics engine
Screening, backtesting, technicals, options analytics, correlations, seasonality and factor models — computed on demand from raw prices, never a stale cache.
It shows its working
Answers arrive with the charts, tables and tool calls behind them, so you can check the number instead of trusting a paraphrase.
Your own documents
Upload filings, decks and research. Ask across them and the answer cites the page it came from.
Agents and workflows
Multi-step research that runs the platform's tools for you — screen, pull the history, compute, compare, then write it up.
MCP, CLI and API
The same command catalogue from Claude, your own agent, a shell or your pipeline. The answer on screen is the answer your job gets at 4am.
You ask
“How does NVDA usually trade through earnings?”
It calls
→ ka.options_expected_move(NVDA)
It answers
NVDA has averaged a 9.2% absolute move on the day after earnings and closed higher 67% of the time. Two in three reactions land between −4.2% and +16.3% — the distribution is skewed right, not symmetric.
Every figure computed live from our own history — not scraped, not summarised.
Or start with